Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1613
    -0.0070 (-0.60%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    52,040.53
    +1,082.16 (+2.12%)
     
  • CMC Crypto 200

    1,384.35
    +71.73 (+5.68%)
     
  • S&P 500

    4,968.45
    -42.67 (-0.85%)
     
  • DOW

    37,919.81
    +144.43 (+0.38%)
     
  • CRUDE OIL

    83.20
    +0.47 (+0.57%)
     
  • GOLD FUTURES

    2,410.60
    +12.60 (+0.53%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge

For Immediate Release

Chicago, IL – June 1, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Fomento Económico Mexicano, S.A.B. de C.V. FMX, NextEra Energy, Inc. NEE, Sanofi SNY, NVIDIA Corp. NVDA and Enbridge Inc. ENB.

Here are highlights from Wednesday’s Analyst Blog:

Top Stock Reports for FEMSA, NextEra Energy and Sanofi

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Fomento Económico Mexicano, S.A.B. de C.V., NextEra Energy, Inc. and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Fomento Económico Mexicano (aka FEMSA) have outperformed the Zacks Beverages - Soft drinks industry over the past year (+33.6% vs. +10.3%). The company is witnessing continued strength at OXXO Mexico, driven by solid traffic, led to a double-digit same-store sales increase. Also, OXXO Gas performed well owing to increased volume recovery and strong operating leverage.

The company’s digital initiatives and business expansion endeavors have also been aiding results. Its efforts to expand in the U.S. specialized distribution segment bodes well.

The company displays strong financial flexibility. However, FEMSA continued to witness gross margin declines due to inflationary pressures.

(You can read the full research report on Fomento Economico Mexicano here >>>)

Shares of NextEra Energy have declined -2.4% over the past year against the Zacks Utility - Electric Power industry’s decline of -14.3%. The company’s nature of business is subject to complex regulations. Risks in operating nuclear units, unfavorable weather conditions and an increase in supply costs adversely impact earnings.

Nevertheless, NextEra Energy continues to expand its operations through organic projects and strategic acquisitions. NextEra has many renewable projects in its backlog and their completion will reduce emissions. The merger of Gulf Power and FPL strengthens NextEra’s position in Florida.

FPL’s customer base is expanding as Florida’s economy improves and continues to boost demand for its services. NextEra has ample liquidity to meet its near-term debt obligations and efficient debt management acts as a tailwind. NEE is expanding its operation in water space through acquisition.

(You can read the full research report on NextEra Energy here >>>)

Sanofi’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past six months (+13.0% vs. +0.5%). The company’s Specialty Care unit is on a strong footing, particularly with the regular label expansion of Dupixent, which has become the key top-line driver for Sanofi.

With outside U.S. revenues accelerating and multiple approvals for new indications, its sales are expected to be higher. Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong. Several data readouts are expected in 2023.

The company has also launched several new drugs in the past couple of years and is expanding its pipeline through M&A deals. However, headwinds include the weak performance of diabetes drugs and recent negative pipeline developments.

(You can read the full research report on Sanofi here >>>)

Other noteworthy reports we are featuring today include NVIDIA Corp. and Enbridge Inc.

Why Haven’t You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.

ADVERTISEMENT

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY) : Free Stock Analysis Report

NextEra Energy, Inc. (NEE) : Free Stock Analysis Report

NVIDIA Corporation (NVDA) : Free Stock Analysis Report

Fomento Economico Mexicano S.A.B. de C.V. (FMX) : Free Stock Analysis Report

Enbridge Inc (ENB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research